Candel Therapeutics
CADL
137 hedge funds and large institutions have $519M invested in Candel Therapeutics in 2026 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 63 increasing their positions, 24 reducing their positions, and 13 closing their positions.
359% more capital inflows, than outflows
Capital inflows: $77.6M | Capital outflows: $16.9M
200% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 13
171% more call options, than puts
Call options by funds: $3.52M | Put options by funds: $1.3M
163% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 24
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
20% more funds holding
Funds holding: 114 → 137 (+23)
9.49% more ownership
Funds ownership: 59.29% → 68.78% (+9.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$20.6M |
| 2 |
BlackRock
New York
|
+$14.1M |
| 3 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$4.5M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.05M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$3.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vestal Point Capital
New York
|
-$5.51M |
| 2 |
HCM
Heights Capital Management
San Francisco,
California
|
-$3.8M |
| 3 |
ExodusPoint Capital Management
New York
|
-$1.11M |
| 4 |
HFF
Halter Ferguson Financial
Carmel,
Indiana
|
-$994K |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$780K |
CADL Hedge Fund Activity: Q2 2026 in Review
137 of the 8,355 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q2 2026, worth a combined $519M — up 144% from $213M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new CADL positions and 13 closed out — a net gain of 26 holders — while 63 added to existing stakes and 24 trimmed.
The largest buyer was State Street, adding an estimated $20.6M. The largest seller was Vestal Point Capital, exiting entirely with an estimated $5.51M sold.
- 137 institutional investors held Candel Therapeutics (CADL) as of Q2 2026, up from 114 in Q1 2026.
- Funds reported $519M of Candel Therapeutics stock for Q2 2026, up 144% quarter-over-quarter.
- 39 funds opened new Candel Therapeutics positions in Q2 2026 and 13 closed out, a net change of +26 holders.
- The largest Candel Therapeutics buyer in Q2 2026 was State Street, an estimated $20.6M added.
- The largest Candel Therapeutics seller in Q2 2026 was Vestal Point Capital, an estimated $5.51M sold.
Based on aggregated 13F filings for Q2 2026.